Additionally, the board has also appointed John Lomoro, the company’s chief financial officer, as acting CEO.
Reportedly, following the resignation of Juliet Singh from her post as president and CEO of Transdel and as a director of board of directors the company has reorganised the management.
The board said: “Juliet played a critical role in the formation, development and growth of the Company. She provided valuable and significant contributions to the company. We appreciate her dedicated service to the company, and wish her the best in her future business endeavors.”
Transdel said it would continue to be fully committed to the success of its lead pain drug Ketotransdel and is excited about the commercial opportunity for this product as well as potentially others utilising its drug delivery system.